Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.
Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, Takahashi K, Mori N.
Alzheimers Dement. 2024 Nov;20(11):8002-8011. doi: 10.1002/alz.14282. Epub 2024 Oct 6.
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group.
J Am Coll Cardiol. 2025 Feb 25;85(7):699-706. doi: 10.1016/j.jacc.2024.11.001. Epub 2024 Nov 18.
Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia.
Nakamura Y, Adachi J, Hirota N, Iba K, Sasajima C, Shimizu K, Nakai M, Takahashi K.
Alzheimers Dement. 2025 Jul;21(7):e70522. doi: 10.1002/alz.70522.
What type of exercise is most effective for people with knee osteoarthritis and co-morbid obesity?: The TARGET randomized controlled trial.
Bennell KL, Nelligan RK, Kimp AJ, Schwartz S, Kasza J, Wrigley TV, Metcalf B, Hodges PW, Hinman RS.
Osteoarthritis Cartilage. 2020 Jun;28(6):755-765. doi: 10.1016/j.joca.2020.02.838. Epub 2020 Mar 19.
Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial.
Shimokawahara H, Nishizaki M, Inami T, Kubota K, Taniguchi Y, Miyagi A, Kikuchi H, Goda A, Miyanaga S, Hashimoto H, Saito AM, Sekimizu M, Matsubara H.
Lancet Respir Med. 2025 Sep;13(9):789-799. doi: 10.1016/S2213-2600(25)00127-4. Epub 2025 Jul 23.
Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
Klausen MK, Kuzey T, Pedersen JN, Justesen SK, Rasmussen L, Knorr UB, Mason G, Ekstrøm CT, Holst JJ, Koob G, Benveniste H, Volkow ND, Knudsen GM, Vilsbøll T, Fink-Jensen A.
BMJ Open. 2025 Jan 8;15(1):e086454. doi: 10.1136/bmjopen-2024-086454.
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
Kadowaki T, Lee SY, Ogawa W, Nishida T, Overvad M, Tobe K, Yamauchi T, Lim S; STEP 6 investigators.
Obes Res Clin Pract. 2024 Nov-Dec;18(6):457-464. doi: 10.1016/j.orcp.2025.01.002. Epub 2025 Jan 16.
Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With Endometriosis-Associated Pain: Two Replicate Phase 3, Randomised, Double-Blind, Studies (SPIRIT 1 and 2).
Adams ED.
J Obstet Gynecol Neonatal Nurs. 2024 Nov;53(6):590-593. doi: 10.1016/j.jogn.2024.09.009. Epub 2024 Oct 10.
Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A, Katsunuma T, Matsumura T, Komazaki H; Nemolizumab-JP04 Study Group.
Br J Dermatol. 2023 Dec 20;190(1):20-28. doi: 10.1093/bjd/ljad268.
Measuring Disability in Glaucoma.
Sotimehin AE, Ramulu PY.
J Glaucoma. 2018 Nov;27(11):939-949. doi: 10.1097/IJG.0000000000001068.
